A Phase I Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of AK3280 in Chinese Healthy Volunteers
Latest Information Update: 12 Feb 2024
At a glance
- Drugs AK 3280 (Primary)
- Indications Hepatic fibrosis; Idiopathic pulmonary fibrosis; Interstitial lung diseases
- Focus Adverse reactions
- Sponsors Ark Biosciences
- 06 Apr 2022 Status changed from recruiting to completed.
- 25 Jun 2021 Status changed from not yet recruiting to recruiting.
- 18 Jun 2021 New trial record